Latest News and Press Releases

Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ,...

Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral...

Allschwil, Switzerland – September 10, 2025Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025,...

Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies ...

Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patients Allschwil, Switzerland & Radnor, Philadelphia...

Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension...

Allschwil, Switzerland – September 1, 2025Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World...

Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204* million convertible bonds maturing...

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a...